Opthea progresses with sozinibercept phase 3 trials for wet AMD

Opthea Limited (ASX: $OPT) is making significant progress in its sozinibercept phase 3 trials for wet age-related macular degeneration (wet AMD). The company has completed enrollment for the COAST trial and estimates the completion of the ShORe trial in the second quarter of calendar year 2024. The topline data from both pivotal phase 3 studies is expected to be available in mid-calendar year 2025.

Executive commentary on sozinibercept and wet AMD treatment

Sozinibercept, a proprietary VEGF-C/D 'Trap' inhibitor, has the potential to address the limitations of anti-VEGF-A therapies. The phase 2b trial demonstrated the superiority of sozinibercept in combination with standard of care therapy, with a well-tolerated safety profile. The completion of COAST enrollment and the estimated completion of the ShORe trial mark significant milestones in our efforts to bring this potential treatment to patients with wet AMD.

Summary of Opthea's progress and outlook

Opthea's completion of COAST enrollment and the estimated completion of the ShORe trial demonstrate the company's commitment to advancing sozinibercept as a potential treatment for wet AMD. With the topline data from both pivotal phase 3 studies expected in mid-calendar year 2025, Opthea is focused on bringing a differentiated combination approach targeting better visual outcomes to the large wet AMD patient population. The company's financial snapshot and corporate activities reflect its dedication to advancing sozinibercept and its potential to disrupt the treatment paradigm for wet AMD.